OncoMatch/Clinical Trials/NCT06050694
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
Is NCT06050694 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies glofitamab for diffuse large b cell lymphoma (dlbcl).
Treatment: glofitamab — This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anthracycline
Prior exposure to any anthracycline
Cannot have received: anti-CD20 antibody (rituximab)
Prior exposure to...rituximab
Cannot have received: CD3-targeted bispecific antibody
Prior exposure to...cluster of differentiation 3 (CD3) targeted bispecific antibody
Lab requirements
Blood counts
Absolute Neutrophil Count (ANC) <1.0 x10^9/L (subjects with bone marrow involvement by lymphoma are eligible regardless of ANC); Hemoglobin (Hgb) ≤ 9 g/dL; Platelets <50 x10^9/L (subjects with bone marrow involvement by lymphoma are eligible regardless of platelet count)
Kidney function
Creatinine clearance <30 mL/min
Liver function
Total serum bilirubin >2 times the upper limit of normal (or <3 times for Gilbert's disease or documented hepatic involvement by lymphoma), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >3 times the upper limit of normal (or >5 times for documented hepatic involvement by lymphoma)
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%, as determined on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) ≥ 50%... Absolute Neutrophil Count (ANC) <1.0 x10^9/L... Hemoglobin (Hgb) ≤ 9 g/dL... Platelets <50 x10^9/L... Total serum bilirubin >2 times the upper limit of normal (or <3 times for Gilbert's disease or documented hepatic involvement by lymphoma), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >3 times the upper limit of normal (or >5 times for documented hepatic involvement by lymphoma)... Creatinine clearance <30 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06050694 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify